| 7.015 0.015 (0.21%) | 05-14 11:55 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.41 | 1-year : | 8.7 |
| Resists | First : | 7.2 | Second : | 7.45 |
| Pivot price | 7.07  |
|||
| Supports | First : | 6.8 | Second : | 5.65 |
| MAs | MA(5) : | 7 |
MA(20) : | 7.1 |
| MA(100) : | 7.67 |
MA(250) : | 8.54 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 56.9 |
D(3) : | 41.9 |
| RSI | RSI(14): 48.6 |
|||
| 52-week | High : | 12.6 | Low : | 4.84 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ KYNB ] has closed above bottom band by 41.5%. Bollinger Bands are 63.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7.16 - 7.2 | 7.2 - 7.23 |
| Low: | 6.88 - 6.93 | 6.93 - 6.98 |
| Close: | 6.92 - 7 | 7 - 7.07 |
Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.
Thu, 14 May 2026
Number of shareholders of Kyntra Bio, Inc. – NASDAQ:KYNB - TradingView
Tue, 12 May 2026
Kyntra Bio (Nasdaq: KYNB) Q1 2026 results show higher revenue, ongoing R&D spend - Stock Titan
Tue, 12 May 2026
Kyntra Bio Inc (KYNB) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic Advances Amidst Challenges - GuruFocus
Mon, 11 May 2026
Kyntra Bio, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:KYNB) 2026-05-11 - Seeking Alpha
Mon, 11 May 2026
Kyntra Bio (KYNB) Q1 2026 Earnings Transcript - AOL.com
Mon, 11 May 2026
Is Kyntra Bio (KYNB) 31.3% Overvalued After Q1 2026 Earnings Bea - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 5 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 4.05e+006 (%) |
| Held by Institutions | 3.56e+006 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.763e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -14.4 |
| Profit Margin | 2 % |
| Operating Margin | 848.6 % |
| Return on Assets (ttm) | -1 % |
| Return on Equity (ttm) | 58.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 1.26 |
| Sales Per Share | -0.01 |
| EBITDA (p.s.) | -0.01 |
| Qtrly Earnings Growth | -4.459e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -0.49 |
| Price to Sales | -2.12113e+006 |
| Price to Cash Flow | 0 |
| Dividend | 112830 |
| Forward Dividend | 113100 |
| Dividend Yield | 1602700% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|